Phase 2 Trial of BCNU Plus O6-Benzylguanine (NSC 637037) in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme
- Determine the activity of carmustine and O6-benzylguanine in patients with newly
diagnosed supratentorial glioblastoma multiforme not requiring immediate radiotherapy.
- Determine the toxicity of this regimen in these patients.
OUTLINE: Patients receive O6-benzylguanine IV over 1 hour followed approximately 1 hour
later by carmustine IV over 1 hour on day 1. Treatment repeats every 6 weeks for a maximum
of 3 courses in the absence of disease progression or unacceptable toxicity. Patients are
then referred for radiotherapy. Patients who demonstrate tumor response after completion of
the third course of chemotherapy receive 6 additional courses after completion of
PROJECTED ACCRUAL: A total of 19-36 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Henry S. Friedman, MD
Duke Cancer Institute
United States: Federal Government